Pioneering Successful Studies for Small & Mid-Size Biopharma

Pioneering Successful Studies for Small & Mid-Size Biopharma

Providing effective strategies and impactful solutions to ensure the success of your early phase studies.  Regardless of your end goal, we’ll lead you down the right path.

Learn More
Behind 8% of all FDA Approvals in the Past 5 Years.

Behind 8% of all FDA Approvals in the Past 5 Years.

Planning, writing and defending regulatory submissions is what we do. In addition to the FDA we have experience with Health Canada, EMA and PMDA.

Learn More
Powered by Data and Data-Driven, it’s in our DNA.

Powered by Data and Data-Driven, it’s in our DNA.

Integrated clinical teams make calculated data-driven decisions throughout each step of a project. Your program will be rooted in biometrics from beginning to end.

Learn More

An Impactful CRO, Committed to Making a Difference.

Helping companies improve and save lives.  Advancing medical innovations through the clinical development & regulatory submission process with a focus on strategy, accuracy, and success.

How Can We Help You Make a Difference?

Contact Us
Learn More


We help pharmaceutical, biotechnology and medical device firms advance through the clinical development process in order to bring their therapies to patients who need them. Explore how Veristat can help you.

Explore Veristat

We Value Expertise & Foster Growth

Employees at Veristat handle complex work that is both rewarding and meaningful. Our team members are dedicated partners to internal colleagues and external clients alike.

Our values include:

  • Teamwork - We are all in this together, we help one another whenever and however we can. 
  • Attentiveness - We listen to each other and to our clients. We learn the facts before drawing conclusions.
  • Creativity - We learn from everything we do and are always thinking about how to provide our clients with smarter, faster, and more impactful services.
  • Flexibility - We go the extra mile to help our clients and our colleagues with open minds and new ideas.
  • Thoughtfulness - We think about issues from multiple angles, with a global outlook and natural curiosity.


If this sounds like an environment you would thrive in, then click below to learn more about us.

Explore More


A TRUE Partnership From The Beginning

Since the day Veristat was formed, our approach has focused on partnership.  We aren’t here to complicate your studies, we are here to be a true extension of your team, to build enduring partnerships, to be a trust-worthy teacher and respected team member.

We are here to be TRUE Partners to You

Explore More


Proficiency In Nearly Every Therapeutic Area

Our teams support amazing, cutting-edge, life-enhancing and life-saving therapies that range from novel vaccines for global pandemics to new approaches for treating fungal infections to the latest immunotherapies to eradicate cancer.   We have the right expertise and therapeutic understanding and creative know-how to help you design, build, and run your clinical development program in any therapeutic area.  

Our current ongoing projects focus for therapies to treat Cancers, Rare Diseases, Neurological Disorders, Cardiovascular Disease, Infectious Diseases and more.

Explore More


Explore Your Career with Veristat

View Open Positions

Latest Updates from Veristat

Blog Image Header_Veristat Congratulates Alnylam on Approval of ONPATTRO

Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™

Continues Collaboration to Provide Regulatory Submission Support for
Additional Patisiran Submissions


SOUTHBOROUGH, MA –  August 20, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. 

Blog Image Header_Veristat Congratulates Agios on TIBSOVO Approval

Veristat Congratulates Agios on the FDA Approval of TIBSOVO®

 The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation


SOUTHBOROUGH, MA –  August 16, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test.

Blog Image Header_Veristat Recognized on INC 5000 2018 List

Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year

 Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That Reach Regulatory Approval


SOUTHBOROUGH, MA –  August 15, 2018 –   Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. 

Within Reach

Veristat teams are positioned around the world. We conduct studies throughout North America, Europe and Australia. Explore our office locations.
Contact Us
Request A Proposal